These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19349131)

  • 1. [Noninvasive tools for the diagnosis of steatosis and fibrosis in patients with NAFLD].
    Castera L
    Gastroenterol Clin Biol; 2009 May; 33(5):405-12. PubMed ID: 19349131
    [No Abstract]   [Full Text] [Related]  

  • 2. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).
    Yoneda M; Yoneda M; Mawatari H; Fujita K; Endo H; Iida H; Nozaki Y; Yonemitsu K; Higurashi T; Takahashi H; Kobayashi N; Kirikoshi H; Abe Y; Inamori M; Kubota K; Saito S; Tamano M; Hiraishi H; Maeyama S; Yamaguchi N; Togo S; Nakajima A
    Dig Liver Dis; 2008 May; 40(5):371-8. PubMed ID: 18083083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive assessment of fibrosis and steatosis in NASH and ASH.
    Angulo P
    Gastroenterol Clin Biol; 2009; 33(10-11):940-8. PubMed ID: 19800187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.
    Kaneda H; Hashimoto E; Yatsuji S; Tokushige K; Shiratori K
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1459-65. PubMed ID: 16911693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.
    Friedrich-Rust M; Müller C; Winckler A; Kriener S; Herrmann E; Holtmeier J; Poynard T; Vogl TJ; Zeuzem S; Hammerstingl R; Sarrazin C
    J Clin Gastroenterol; 2010 Jan; 44(1):58-65. PubMed ID: 19581812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease.
    Adams LA; Angulo P
    Clin Liver Dis; 2007 Feb; 11(1):25-35, viii. PubMed ID: 17544970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.
    Wieckowska A; McCullough AJ; Feldstein AE
    Hepatology; 2007 Aug; 46(2):582-9. PubMed ID: 17661414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.
    Munteanu M; Ratziu V; Morra R; Messous D; Imbert-Bismut F; Poynard T
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):187-91. PubMed ID: 18568141
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnostic power of fibroscan in predicting liver fibrosis in nonalcoholic fatty liver disease.
    Alisi A; Pinzani M; Nobili V
    Hepatology; 2009 Dec; 50(6):2048-9; author reply 2049-50. PubMed ID: 19937689
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
    Bugianesi E; Marchesini G; Gentilcore E; Cua IH; Vanni E; Rizzetto M; George J
    Hepatology; 2006 Dec; 44(6):1648-55. PubMed ID: 17133473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do not trivialize the Fibroscan examination, value its accuracy.
    Rigamonti C; Fraquelli M
    J Hepatol; 2007 Jun; 46(6):1149. PubMed ID: 17445941
    [No Abstract]   [Full Text] [Related]  

  • 12. Liver cirrhosis and steatosis comparison of the severity of biochemical changes.
    Fassati P; Horejsi J; Jezkova Z; Spizek J
    Tijdschr Gastroenterol; 1978; 21(2):113-22. PubMed ID: 705763
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of blood tests for liver fibrosis specific or not to NAFLD.
    Calès P; Lainé F; Boursier J; Deugnier Y; Moal V; Oberti F; Hunault G; Rousselet MC; Hubert I; Laafi J; Ducluzeaux PH; Lunel F
    J Hepatol; 2009 Jan; 50(1):165-73. PubMed ID: 18977552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Magnetic resonance imaging for quantifying hepatis steatosis and hepatic fibrosis].
    Van Beers B
    Bull Mem Acad R Med Belg; 2009; 164(1-2):44-50; discussion 51-2. PubMed ID: 19718953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are non-invasive tests accurate enough to predict hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD)?
    Chavez-Tapia NC; Tiribelli C
    Gut; 2008 Oct; 57(10):1351-3. PubMed ID: 18791116
    [No Abstract]   [Full Text] [Related]  

  • 16. Cryptogenic cirrhosis and NAFLD: are they related?
    Maheshwari A; Thuluvath PJ
    Am J Gastroenterol; 2006 Mar; 101(3):664-8. PubMed ID: 16464222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon.
    Charlton M
    Am J Gastroenterol; 2007 Feb; 102(2):409-11. PubMed ID: 17311653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New diagnostic method for liver fibrosis and cirrhosis.
    Han KH; Yoon KT
    Intervirology; 2008; 51 Suppl 1():11-6. PubMed ID: 18544943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic evaluation of nonalcoholic fatty liver disease.
    Adams LA; Talwalkar JA
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S34-8. PubMed ID: 16540765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).
    Ali R; Cusi K
    Ann Med; 2009; 41(4):265-78. PubMed ID: 19353360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.